ScholarLens Back to search
2012•Journal of Nantong UniversityRequires access

Therapeutic effect of interferon α-2a on treating chronic hepatitis B

Xing Wang

Open publisher page 0 citations

Abstract

Objective: To compare the clinic effect and safety of PEG-IFNα-2a and IFNα-1b for treating chronic hepatitis B(CHB) cases.Methods: 49 CHB cases were divided into 2 groups:26 cases in PEG-IFNα-2a group(treatment group) and 23 cases in IFNα-1b group(control group).The liver function,HBV-DNA levels,change of hepatitis B virus marker,and side-efects were observed.Results: At week 48 of treatment,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(all P0.05).At week 48 of follow-up,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(P0.01,P0.01,P0.025).Conclusion: PEG-IFNα-2a in the treatment of CHB has advantage over IFNα-1b and has a better safety.

About this research paper

What this paper is about

Objective: To compare the clinic effect and safety of PEG-IFNα-2a and IFNα-1b for treating chronic hepatitis B(CHB) cases.Methods: 49 CHB cases were divided into 2 groups:26 cases in PEG-IFNα-2a group(treatment group) and 23 cases in IFNα-1b group(control group).The liver function,HBV-DNA levels,change of hepatitis B virus marker,and side-efects were observed.Results: At week 48 of treatment,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(all P0.05).At week 48 of follow-up,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(P0.01,P0.01,P0.025).Conclusion: PEG-IFNα-2a in the treatment of CHB has advantage over IFNα-1b and has a better safety.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective: To compare the clinic effect and safety of PEG-IFNα-2a and IFNα-1b for treating chronic hepatitis B(CHB) cases.Methods: 49 CHB cases were divided into 2 groups:26 cases in PEG-IFNα-2a group(treatment group) and 23 cases in IFNα-1b group(control group).The liver function,HBV-DNA levels,change of hepatitis B virus marker,and side-efects were observed.Results: At week 48 of treatment,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(all P0.05).At week 48 of follow-up,HBeAg negative rate,HBV-DNA negative rate and HBeAg/Anti-HBe change rate in treatment group were significantly higher than those in control group(P0.01,P0.01,P0.025).Conclusion: PEG-IFNα-2a in the treatment of CHB has advantage over IFNα-1b and has a better safety.

Key concepts: HBeAg, Medicine, Chronic hepatitis, Gastroenterology, Interferon, Internal medicine, Hepatitis B, Hepatitis B virus

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Therapeutic effect of interferon α-2a on treating chronic hepatitis B — Research Paper | ScholarLens